Neil Mathews - Concepedia

Author

Neil Mathews

GlaxoSmithKline (United Kingdom)

Also Known As

Neil Mathews

Publications

807

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United Kingdom)Institute of Medicinal Plant Development Imperial College London

About

Neil Mathews is an author at GlaxoSmithKline (United Kingdom) specializing in drug discovery, pharmacotherapy, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	289
2	Natural Sciences	6	6	217
3	Biochemistry	6	6	218
4	Engineering	1	1	19
5	Biomolecular Engineering	1	1	19

Neil Mathews

Publications

789

Citations

H-Index

Page 1

	Year	Citations
Identification of 1,5-Naphthyridine Derivatives as a Novel Series of Potent and Selective TGF-β Type I Receptor Inhibitors Françoise Gellibert, James M. Woolven, Marie-Hélène Fouchet, Journal of Medicinal Chemistry	2004	217
Discovery of 4-{4-[3-(Pyridin-2-yl)-1<i>H</i>-pyrazol-4-yl]pyridin-2-yl}-<i>N</i>-(tetrahydro-2<i>H</i>- pyran-4-yl)benzamide (GW788388): A Potent, Selective, and Orally Active Transforming Growth Factor-β Type I Receptor Inhibitor Françoise Gellibert, Anne‐Charlotte de Gouville, James M. Woolven, Journal of Medicinal Chemistry ImmunologyReceptor InhibitorPharmacotherapyChemical BiologyPharmaceutical Chemistry	2006	102
A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein John P. DeVincenzo, Dereck Tait, John Efthimiou, Antimicrobial Agents and Chemotherapy	2019	84
State of the Art in Respiratory Syncytial Virus Drug Discovery and Development G. Stuart Cockerill, James A. D. Good, Neil Mathews Journal of Medicinal Chemistry Viral ReplicationRespiratory Syncytial VirusMedicineImmunologyAntiviral Drug Development	2018	71
Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion G. Stuart Cockerill, Richard Angell, Alexandre F. Bedernjak, Journal of Medicinal Chemistry	2021	66
Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors Paul Beswick, Sharon Bingham, C. Bountra, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryBiochemistryMedicineNatural SciencesPharmacological Agent	2004	46
Synthesis and Serotonergic Activity of Substituted 2,<i>N</i>-Benzylcarboxamido-5-(2-ethyl-1-dioxoimidazolidinyl)-<i>N</i>,<i>N</i>-dimethyltrypt- amine Derivatives: Novel Antagonists for the Vascular 5-HT<sub>1B</sub>-like Receptor Gerard P. Moloney, Graeme R. Martin, Neil Mathews, Journal of Medicinal Chemistry	1999	43
A Novel Series of 2,5-Substituted Tryptamine Derivatives as Vascular 5HT<sub>1B/1D</sub> Receptor Antagonists Gerard P. Moloney, Alan D. Robertson, Graeme R. Martin, Journal of Medicinal Chemistry	1997	34
Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors Martin E. Swarbrick, Paul Beswick, Robert J. Gleave, Bioorganic & Medicinal Chemistry Letters Combinatorial ChemistryMedicinal ChemistryBiochemistryMedicineNatural Sciences	2009	22
Identification and optimisation of a novel series of pyrimidine based cyclooxygenase-2 (COX-2) inhibitors. Utilisation of a biotransformation approach Paul Beswick, Andrew P. Blackaby, C. Bountra, Bioorganic & Medicinal Chemistry Letters Novel SeriesBiochemistryMedicineRational Drug DesignPharmacological Agent	2009	21

Page 1